A research team at Florida State University's Institute of Molecular Biophysics and Department of Chemistry and Biochemistry ...

Researchers at the Department of Cell and Molecular Biology, Karolinska Institutet have captured the first detailed molecular ...

Arrowhead Pharmaceuticals (ARWR) just started dosing patients in its Phase 1/2a trial for ARO-MAPT, an RNA interference therapy aimed at tauopathies like Alzheimer’s, and the stock has been reacting ...

This article explores how challenges such as sequence optimization, immune activation and off-target effects are being ...

Arrowhead Pharmaceuticals, Inc. today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, the company's investigational RNA interference (RNAi) therapeutic being ...

IQ Consortium experts explain how advanced chromatographic and analytical strategies are improving the bioanalysis, ...

The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1, also called SRP-1003, an investigational RNA interference ("RNAI") ...

Arrowhead Pharmaceuticals, Inc. ( (ARWR)) has released its Q4 earnings. Here is a breakdown of the information Arrowhead Pharmaceuticals, Inc. presented to its investors. Arrowhead Pharmaceuticals, ...

It was 2012 when Love Dalén, a paleogeneticist at Stockholm University, first laid eyes upon a special specimen on a lab table in eastern Siberia. "Our Russian collaborators said, 'Come here into this ...

BEIJING and GOTHENBURG, Sweden, Oct. 24, 2025 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has ...

The U.S. Environmental Protection Agency has approved the registration of Norroa, the first-ever RNA-based treatment for varroa mites, the leading threat to honeybee colonies. The new product from ...